The Top Line

A year in review and what 2026 holds for biopharma and healthcare

From data to decisions: how Walgreens is powering smarter pharma strategies (Sponsored)

The biopharma dealmaking landscape and what to expect in 2026

In this episode of The Top Line, host Ayla Ellison introduces a discussion on the biopharma industry's deal-making landscape. Kevin Dunleavy interviews Arda Ural, EY America's Life Sciences sector leader, about the fluctuations in M&A, venture financing, and licensing deals, particularly in light of COVID-19, economic ...

Advocacy, access and the future of cancer care take center stage in new Health Matters episode (Sponsored)

2025’s Fiercest Women in Life Sciences are changing the game

Bayer’s collaborative model: Breaking silos to accelerate impact (Sponsored)

Inside Foresight’s mission to redefine cancer monitoring (Sponsored)

Biopharma industry gathers momentum in Q3

PreCheck pulse check: What the industry is saying about FDA’s production initiative

How Pharma Can Build Trust and Reach Patients in Health Marketplaces (Sponsored)

Biotech Graveyard

Fierce 15: Where are they now?

Salesforce’s Mark Sullivan: AI and agentic systems will redefine life sciences (Sponsored)

Unpacking the FDA transparency push on CRLs

How Boehringer Ingelheim is buttressing its US business

AI is changing drug safety, but governance sets the guardrails (Sponsored)

A whirlwind week for pharma

Fierce Biotech's Fierce 15

Rebuilding trust in pharma in the age of misinformation

Schrödinger taps AI to speed drug discovery (Sponsored)